ClinicalTrials.gg

Program

TQC3927

A development code. Also written as “TQC3927 powder for inhalation” and “TQC3927 inhalation aerosol”.

In Sino Biopharmaceutical's pipeline, MABA双靶. Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Sino Biopharmaceutical.

Furthest: phase 2, since Jun 3, 20263 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical30 open or runningphase 2since Jun 3, 2026Apr 29, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQC3927, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2024First study: phase 1 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06408285 · 60 enrolled · China
  2. Nov 22, 2024Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT06711991 · 48 enrolled · China
  3. Jun 3, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructivePhase 2 reachedNCT07633314 · 90 enrolled · China

TargetBeta

“MABA双靶”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TQC3302Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07633314Pulmonary Disease, Chronic Obstructive · China2SuspendedDec 202690
NCT06711991Pulmonary Disease, Chronic Obstructive · China1CompletedAug 11, 202548
NCT06408285Pulmonary Disease, Chronic Obstructive · China1CompletedAug 19, 202460

How it is read

Names in the registry

  • “TQC3927 powder for inhalation”, 2 entries
  • “TQC3927 inhalation aerosol”, 1 entry

Codes read as this program: TQC3927.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.